Probodies, anticancer
How CytomX's Probodies improve safety across immuno-oncology modalities
How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities. CytomX Therapeutics Inc. is using its Probody platform to restrict activity to tumors by capitalizing on enzymes unique to the tumor microenvironment. The company believes that by improving safety, its technology can expand the range of targets, indications and therapeutic combinations possible in cancer immunotherapy.
Over the past eight weeks, CytomX has presented the first data on its Probody platform for three different types of cancer immunotherapies - checkpoint inhibitors, antibody-drug conjugates (ADCs) and T cell-engaging bispecific antibodies (TCBs) - and announced a new partnership on a fourth, CAR-NK cells...